Mark S. Blumenkranz, Director at Avalanche Biotechnologies, Inc. ([AAVL]), sold 5,000 shares at $40.08 ($200K) on 2015-06-05, disclosed to the SEC on 2015-06-08.
Scheduled sale ($200k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| AAVL | SELL | 2015-05-21 | $37K | — | Filing → |
| [AAVL] | SELL | 2015-05-18 | $798K | — | Filing → |
| [AAVL] | SELL | 2015-05-13 | $25K | — | Filing → |